- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg)
- Drug
- Lead sponsor
- PhenoNet, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bipolar Disorder
- Interventions
- Riluzole, Placebo
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Major Depression
- Interventions
- Lamotrigine, Ketamine, Riluzole
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo tablets, Riluzole
- Drug · Other
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
- Conditions
- Tourette Syndrome
- Interventions
- D-serine, Riluzole, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atrial Fibrillation Paroxysmal
- Interventions
- Riluzole 50 MG
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Social Anxiety Disorder, Performance Anxiety
- Interventions
- BHV-0223, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Male and Female Subjects
- Interventions
- Y-4 tablet, Pregabalin capsule, Riluzole tablet
- Drug
- Lead sponsor
- Neurodawn Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
- Interventions
- BHV-0223
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 5
- States / cities
- Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
- Conditions
- Inflammation, Fatigue
- Interventions
- Riluzole, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- PTSD
- Interventions
- Riluzole, Placebo (for Riluzole)
- Drug
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Syracuse, New York
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo (for MN-166), MN-166, riluzole
- Drug
- Lead sponsor
- MediciNova
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK-2017357, Placebo, Riluzole 50 MG
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 11
- States / cities
- Fresno, California • La Jolla, California • Orange, California + 8 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
- Drug
- Lead sponsor
- AB Science
- Industry
- Eligibility
- 18 Years to 81 Years
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more